Organovo Holdings, Inc., a biotechnology company, provides therapeutic and drug profiling capabilities based on its 3D bioprint tissues that emulate human biology and diseases. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds. It is also developing in vivo liver tissues to treat a range of rare, life-threatening diseases. In addition, the company offers preclinical in vitro disease modeling platforms, including a range of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis conditions. Further, it involved in various programs to develop its NovoTissues transplantable tissues to address various serious unmet medical needs in adult and pediatric populations primarily focusing on liver disease. The company was founded in 2007 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ONVO
CUSIPN/A
Phone858-224-1000
Debt
Debt-to-Equity RatioN/A
Current Ratio10.06
Quick Ratio9.88
Price-To-Earnings
Trailing P/E Ratio-4.59
Forward P/E Ratio-5.88
P/E GrowthN/A
Sales & Book Value
Annual Sales$4.60 million
Price / Sales35.51
Cash FlowN/A
Price / CashN/A
Book Value$0.40 per share
Price / Book3.68
Profitability
EPS (Most Recent Fiscal Year)($0.32)
Net Income$-34,800,000.00
Net Margins-756.09%
Return on Equity-68.75%
Return on Assets-62.71%
Miscellaneous
Employees75
Outstanding Shares111,130,000
Organovo (NASDAQ:ONVO) Frequently Asked Questions
What is Organovo's stock symbol?
Organovo trades on the NASDAQ under the ticker symbol "ONVO."
How were Organovo's earnings last quarter?
Organovo Holdings Inc (NASDAQ:ONVO) issued its quarterly earnings data on Tuesday, June, 5th. The medical research company reported ($0.07) EPS for the quarter, hitting analysts' consensus estimates of ($0.07). The medical research company earned $1.11 million during the quarter, compared to analyst estimates of $1.30 million. Organovo had a negative return on equity of 68.75% and a negative net margin of 756.09%. View Organovo's Earnings History.
What price target have analysts set for ONVO?
4 Wall Street analysts have issued twelve-month target prices for Organovo's stock. Their forecasts range from $3.00 to $5.00. On average, they expect Organovo's stock price to reach $4.00 in the next year. View Analyst Ratings for Organovo.
What are Wall Street analysts saying about Organovo stock?
Here are some recent quotes from research analysts about Organovo stock:
- 1. According to Zacks Investment Research, "Organovo Holdings, Inc. is a three-dimensional biology company focused on delivering breakthrough bioprinting technology and creating tissue on demand for research and medical applications. Its NovoGen 3D printing technology is a platform that works across various tissue and cell types. Organovo Holdings, Inc. is based in San Diego, California. " (6/2/2018)
- 2. BTIG Research analysts commented, "Reset Delays Ramp; Trimming PT From $5 to $3 We are updating our model and price target to reflect Q3 results and a slower than anticipated revenue ramp as a result of the company’s strategy focus toward fast-growing, higher margin compound screening and disease modeling. We continue to feel ONVO is a long-term investment with sizable market opportunities ($3B+) but as the technology is quite new, predicting the rate at which pharma and research partners will adopt this new technology can be tricky. As our model now incorporates more risk in the near-term given the change in strategy, our revised DCF yields a $3 PT, down from $5 previously. We maintain our Buy rating. Commentary on revenue mix is encouraging. In the call, management noted a 60%/40% split between repeat and new orders in the first half of the fiscal year, consistent with the mix seen in Fiscal 2017. Additionally, average revenue per order also continues to rise, driven by the aforementioned shift to higher value disease modeling. Finally, management also suggested the potential for a few of its clients to shift from single project to annual revenue commitment contracts over the next couple of quarters. Valuation: Our price target is $3, based on a DCF analysis that assumes a WACC of 15% and a LT growth rate of 3%. Risks follow on page 6." (11/16/2017)
Who are some of Organovo's key competitors?
Some companies that are related to Organovo include Fate Therapeutics (FATE), Novavax (NVAX), BioCryst Pharmaceuticals (BCRX), Mesoblast (MESO), CASI Pharmaceuticals (CASI), Scholar Rock (SRRK), Nightstar Therapeutics (NITE), Vericel (VCEL), Surface Oncology (SURF), MeiraGTx (MGTX), PDL BioPharma (PDLI), Idera Pharmaceuticals (IDRA), NanoString Technologies (NSTG), Adverum Biotechnologies (ADVM) and Osiris Therapeutics (OSIR).
Who are Organovo's key executives?
Organovo's management team includes the folowing people:
- Mr. Taylor J. Crouch, CEO, Pres & Director (Age 58)
- Mr. Craig Kussman MBA, Chief Financial Officer (Age 59)
- Dr. Sharon Collins Presnell Ph.D., Chief Scientific Officer (Age 49)
- Ms. Jennifer Kinsbruner Bush J.D., Sr. VP, Gen. Counsel, Corp. Sec. & Compliance Officer (Age 43)
- Mr. Paul Gallant, Gen. Mang. (Age 53)
Has Organovo been receiving favorable news coverage?
News coverage about ONVO stock has been trending somewhat positive on Tuesday, Accern Sentiment reports. The research group identifies negative and positive news coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Organovo earned a media sentiment score of 0.13 on Accern's scale. They also gave news articles about the medical research company an impact score of 47.78 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near future.
Who are Organovo's major shareholders?
Organovo's stock is owned by a variety of of institutional and retail investors. Top institutional investors include ARK INVESTMENT MANAGEMENT LLC (10.84%), BlackRock Inc. (5.48%), UBS Group AG (0.80%), LPL Financial LLC (0.11%) and First Republic Investment Management Inc. (0.10%). Company insiders that own Organovo stock include Eric David and Keith Murphy. View Institutional Ownership Trends for Organovo.
Which institutional investors are selling Organovo stock?
Which institutional investors are buying Organovo stock?
How do I buy shares of Organovo?
Shares of ONVO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Organovo's stock price today?
One share of ONVO stock can currently be purchased for approximately $1.47.
How big of a company is Organovo?
Organovo has a market capitalization of $167.80 million and generates $4.60 million in revenue each year. The medical research company earns $-34,800,000.00 in net income (profit) each year or ($0.32) on an earnings per share basis. Organovo employs 75 workers across the globe.
How can I contact Organovo?
Organovo's mailing address is 6275 NANCY RIDGE DRIVE SUITE 110, SAN DIEGO CA, 92121. The medical research company can be reached via phone at 858-224-1000 or via email at [email protected]
MarketBeat Community Rating for Organovo (ONVO)
MarketBeat's community ratings are surveys of what our community members think about Organovo and other stocks. Vote "Outperform" if you believe ONVO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ONVO will underperform the S&P 500 over the long term. You may vote once every thirty days.
